Brief: 4Dmt Announces Exclusive License Agreement With Otsuka Pharmaceutical For Development And Commercialization Of 4D-150 In Asia-Pacific
31/10/2025 03:05
Oct 30 (Reuters) - 4D Molecular Therapeutics Inc FDMT.O: 4DMT ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH OTSUKA PHARMACEUTICAL CO., LTD. FOR DEVELOPMENT AND COMMERCIALIZATION OF 4D-150 IN ASIA-PACIFIC 4D MOLECULAR THERAPEUTICS INC - 4DMT TO RECEIVE $85 MILLION UPFRONT AND $50 MILLION COST SHARING 4D MOLECULAR THERAPEUTICS INC - UP TO $336 MILLION IN POTENTIAL MILESTONES AND ROYALTIES Source text: ID:nGNX1tJrvb Further company coverage: FDMT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings